The US Food and Drug Administration said 1 February it will share information about manufacturing deficiencies identified in remote records reviews conducted in lieu of or in advance of pre-approval and pre-license inspections and will consider sponsors’ responses to the findings.
The agency may later expand the policy to include records reviews conducted in lieu of or in